Dominate.

With lung SBRT. French researchers milked the infamous STARS/ROSEL pooled data in a complicated cost-effectiveness analysis, proclaiming lung SBRT to be dominant over lobectomy (i.e., it both costs less and produces more quality-adjusted life years). | Paix, Radiother Oncol 2018